IPSC-CMs
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Food and Drug Administration is forecasting the purchase of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) to be used for in-vitro research. This procurement is managed through the FDA's National Center for Toxicological Research, with the Nctr Acquisition Liaison serving as the primary program point of contact for inquiries. As this is currently listed as a forecast, a specific contracting officer has not yet been assigned and further details regarding the solicitation number, NAICS code, and place of performance are pending. Interested parties can monitor the opportunity through the official HHS industry forecast portal.
General Info
Place of Performance
USASet-Aside
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Organization & Contact Information
Full Description
Similar Contracts
Same NAICS industry code
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
